POM-V Prescription Required

Ekyflogyl 1.8mg/ml + 8.7mg/ml Gel for Horses

Active ingredients: Lidocaine, Prednisolone

Form

Gel

Species

Horses

Manufacturer

AUDEVARD

VMD MA No.

44684/4004

What it's used for

For the alleviation of pain and inflammation associated with localised musculoskeletal disorders.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Lidocaine + Prednisolone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Ekyflogyl 1.8mg/ml + 8.7mg/ml Gel for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the alleviation of pain and inflammation associated with localised musculoskeletal
disorders.

Cutaneous use. Apply the product to a localised area over the underlying lesion with
a small brush (paintbrush or similar). If needed, a non-compressive dressing may be
applied to cover the treated area. Apply 11 to 32 ml twice daily, corresponding to 6 to
18 actuations of the pump dispenser, depending on the nature of the lesion.
Pump must be primed twice before use.
Continue the treatment until the clinical signs are resolved, but do not use the
product for more than 12 days.
To open the device, turn the snap cap as indicated on the top. After each use, close
the device by turning the snap cap in the opposite direction.

Do not use in known cases of hypersensitivity to the active substances or to any of
the excipients. See section 4.7. Do not use in horses with hepatic or renal disease.
The product should not be used in horses with ongoing viral, or fungal infections or in
immunocompromised horses.

Local reactions (pain, heat, loss of hair, squamosis/scaly skin, burn marks, swelling)
have been very rarely reported.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the
course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

Revised: March 2022
AN: 02776/2021

None.

Revised: March 2022
AN: 02776/2021

Special precautions for use in animals
This product should not be used on irritated or broken skin.
Oral ingestion of the product by treated animals or animals having contact with
treated animals should be avoided.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
- This product may cause allergic reactions. People with known hypersensitivity to
prednisolone, lidocaine, other local anaesthetics or dimethyl sulfoxide (DMSO)
should not handle the product.
- Prednisolone may cause harm to the unborn foetus. Pregnant women should
therefore not handle this product.
- This product may be harmful after dermal and oral exposure. Lidocaine may form
genotoxic metabolites in humans. A long-term toxicology study in rats has shown
evidence that these metabolites can also induce carcinogenic effects at high doses.
The product is also irritating to the skin (reactions including erythema and pruritus)
and to the eye.
- Avoid contact with skin, eye and mouth, including hand-to-mouth and hand-to-eye
contact. Wash hands after use. In the event of accidental contact with the skin or
eyes, rinse thoroughly with water.
- Personal protective equipment consisting of impermeable single-use protective
gloves should be worn when handling the veterinary medicinal product or touching
the treated area.
- Prevent children from touching the treated horse during the period of treatment and
12 days after the end of the treatment.
- Do not touch the treated area. If this is necessary for horse care, wear impermeable
single-use protective gloves.
- In the event of accidental ingestion or persistent skin or eye irritation, seek medical
advice immediately and show the package leaflet or the label to the physician.
- Additional material or devices used to apply the product such as a brush should be
cleaned up thoroughly or disposed of according to local requirements.
- Keep the bottle with the dosing pump in the outer carton and in safe place out of the
sight and reach of children until ready to use. The device should be locked after each
use (see details in section 4.9).

Do not use with other products, in particular topical products on the treated area.

Do not store above 30°C
Store in the outer carton in order to protect from light

Not authorised for use in horses intended for human consumption.

Revised: March 2022
AN: 02776/2021
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.